mechanisms to evade the immune system and progress. Among them, CD4 + CD25 + regulatory T (Treg) cells, myeloid-derived suppressor cells (MDSC), and type II NKT cells represent major cell types responsible for immunosuppression in tumor-bearing hosts. [14] [15] [16] Treg cells can suppress the effects of anticancer immunotherapy, and there is a correlation between their presence at local tumor sites and an unfavorable prognosis. 17, 18 In cancer-bearing hosts, the number of MDSC increases and can inhibit T cell responses. 19, 20 NKT cells comprise 2 subsets: type I NKT cells promote antitumor immunity, and type II NKT cells suppress tumor immunity. The simultaneous stimulation of both NKT cells in wild type (WT) immune-competent mice diminished protection against tumors in vivo in 2 different tumor models, 21 suggesting that type II NKT cells dominate type I NKT cells. In contrast, in a study using Jα-18 −/− mice lacking type I NKT cells, but still retaining type II NKT cells, the absence of type I NKT cells resulted in an increase in the suppression by type II NKT cells, 21 suggesting that type I NKT cells somewhat reduce the suppressive effect of type II NKT cells. Thus, the 2 subsets cross-regulate each other, forming an immunoregulatory axis. 21 Although the blockade of such immunosuppressors is a promising strategy for enhancing antitumor immunity, targeting one cell type is not always sufficient for tumor rejection because of the redundancy of immune regulatory cells. In a subcutaneous murine syngeneic CT26 colorectal tumor model, Treg cells are known to be key immunosuppressors; their depletion completely abrogated tumors in WT mice. [22] [23] [24] However, in CD1d −/− mice lacking both type I and type II NKT cells, but still possessing Treg cells, tumor growth was marginally suppressed compared with WT mice. 24, 25 These results suggest that the loss of negative regulation by lacking type II NKT cells has stronger impact than that of antitumor effect by lacking type I NKT cells and that the lack of both NKT cell types plays some role in overcoming negative immune regulation.
In earlier reports of JTT as a cancer agent, studies were focused on immune-competent hosts. Thus, we hypothesized that JTT can exert antitumor effects in CD1d −/− mice, in which immunosuppression was partially relieved due to the lack of NKT cells.
In the present study, we showed the oral administration of JTT inhibited subcutaneously inoculated CT26 tumor growth in BALB-CD1d −/− mice. As expected, this did not occur in immune-competent WT BALB/c mice. JTT's antitumor effects in CD1d −/− mice were mediated by CD8 + T cells. We also exclusively detected tumor-reactive cytotoxic T-lymphocytes (CTLs) in JTT-treated mice with well-controlled tumors. Additionally, we demonstrated a reduced number of CD11b + Ly6G + Ly6C lo polymorphonuclear (PMN)-MDSC and an increased number of degranulation marker CD107a + CD8 + T cells. These were concomitantly observed in tumor-infiltrating lymphocytes (TILs) from CT26-bearing CD1d −/− mice treated with JTT, probably resulting in tumor growth inhibition. Our data indicate that, in the absence of NKT cells, CD8 + T cell-mediated antitumor immunity may be augmented by JTT and that JTT is a useful adjuvant for combating cancers in conjunction with the strategy for removing immunosuppression.
Materials and Methods

Mice
We purchased inbred BALB/c mice from Charles River Japan (Tokyo, Japan). We purchased BALB/c CD1d −/− mice from Jackson Laboratory (Bar Harbor, ME). We established 26 and bred transgenic mice expressing TCR α and β genes of a murine CTL (cytotoxic T lymphocyte) clone RT1 27 (Tg-RT1) in our colony. These were specific for peptide P18-I10 restricted by D d class I MHC (major histocompatibility complex) molecules, carrying the genetic background of BALB/c (H-2D d ). Mice were housed in groups of 5 in filter cages and maintained in a temperaturecontrolled, specific-pathogen-free animal facility. They were exposed to a constant 14-hour light-10-hour dark cycle, with free access to water and ad libitum access to food as indicated. We included female mice >6 weeks old 
Diets Containing Japanese Kampo Medicine JTT
JTT, comprising 10 herbs (Table 1 ; http://mpdb.nibiohn. go.jp/stork/), was provided as a preservative-free pure powder by Tsumura & Co (Tokyo, Japan). As a control, we used MF diet (Oriental Yeast Co, Tokyo, Japan). Mice were fed a control diet or a control diet mixed with JTT (2.0%; designated JTT diet). Body weight and food intake in mice were measured 3 times a week using an electronic scale for 42 days (from 14 days prior to tumor inoculation to 28 days after tumor challenge). The amount of food intake in the JTT-diet group was almost equivalent to that in the control-diet group in CD1d −/− mice (Supplementary Figure 1C ; available online). Interestingly, BALB/c mice consumed more of the JTT diet than the control diet (Supplementary Figure 1A) . However, there were no differences in body weight between the control-diet and the JTT-diet groups of CD1d −/− or BALB/c mice (Supplementary Figure 1B and D).
Tumor Cell Lines
We purchased the N-nitro-N-methylurethane-induced BALB/c murine colon carcinoma CT26 cell line from the American Type Culture Collection (ATCC; Manassas, VA). The cell line was maintained in RPMI-1640 complete medium (ThermoFisher Scientific, Inc, Waltham, MA). The medium was supplemented with 10% fetal calf serum (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), penicillin (100 U/mL), streptomycin (100 µg/mL), L-glutamine (2 mM); sodium pyruvate (1 mM), nonessential amino acids, HEPES (10 mM), MEM (minimum essential medium) vitamin solution, and 2-mercaptoethanol (5 × 10 −5 M).
In Vivo Tumor Assay and Antibody Treatment
Prior to tumor challenge, BALB/c and CD1d −/− mice were fed the control or JTT diet for 14 days. We prepared a single-cell suspension of CT26 cells in phosphate-buffered saline (PBS; 5 × 10 4 cells in 200 µL) and then subcutaneously injected in the mice on day 0. The mice were fed the same diet for 28 days post-tumor inoculation. In a subset of experiments, CD1d −/− mice fed the JTT diet were injected intraperitoneally (ip) with 0.2 mg of anti-CD8 monoclonal antibody (clone, 2.43, cat. no. BE0061; Bio X Cell, West Lebanon, NH). Time points were as follows: 1 and 2 days prior to the inoculation with tumor cells and 4, 7, 10, and 14 days following the inoculation with tumor cells. The tumor area was measured 3 times a week using a caliper gauge. The measurements were calculated as tumor length (mm) × width (mm). When the tumor area was <100 mm 2 on day 28 post-tumor challenge, the mice were considered as "survived." 24
Isolation of TILs
To isolate TILs, tumors were resected from mice and digested with 1 mg/mL collagenase (Roche Diagnostics GmbH, Mannheim, Germany) for 45 minutes at 37°C. The product was then gently crushed to homogenize the mass and then filtrated with a nylon mesh. To purify TILs, the leukocytes obtained through the latter process were further separated from contaminating tumor cells by lympholyte-M (CEDARLANE, Burlington, NC), according to the manufacturer's instructions.
Flow Cytometric Analysis
To determine the surface molecule expression of the cells, we performed flow cytometry using a FACSCanto II flow cytometer (Becton Dickinson Immunochemical Systems, Mountain View, CA). Specifically, to reduce nonspecific antibody binding to Fc receptors, isolated cells were incubated with 0.5 µg of anti-CD16/CD32 (clone 2.4G2, catalog number: 14-0161; eBioscience, Inc, San Diego, CA) at 4°C for 15 minutes. Subsequently, relevant antibodies were used to stain for 30 minutes at 4°C. The cells were then washed once with 2 mL of cold Dulbecco's phosphate buffer saline (DPBS; ThermoFisher Scientific) and analyzed. We used the following antibodies: APC/Cy7-conjugated anti-CD3 (clone 145-2C11, catalog number: 100329), FITCconjugated anti-CD4 (clone RM4-5, catalog number: 100510), FITC-conjugated anti-CD8β (clone YTS156.7.7, catalog number: 126606), APC-conjugated anti-CD107a (clone 1D4B, catalog number: 121613), PECy7-conjugated anti-CD11b (clone M1/70, catalog number: 101215), APC/ Cy7-conjugated anti-CD45 (clone 30-F11, catalog number: 103116), FITC-conjugated anti-Ly6G (clone 1A8, catalog number: 127605), and PE-conjugated anti-Ly6C (clone HK1.4, catalog number: 128007). We purchased all the antibodies from Biolegend (San Diego, CA). Dead cells were gated based on the uptake of propidium iodide. For intracellular Foxp3 staining to detect CD4 + Foxp3 + T cells, following surface staining with anti-CD3 and anti-CD4 (in case of spleen cells) or with anti-CD3, anti-CD4, and anti-CD45 (in case of TILs), stained cells were washed once with 2 mL of cold DPBS. Cells were then fixed with 1 mL of Fixation/Permeabilization solution (eBioscience) at 4°C for 30 minutes. The fixed cells were then washed twice with 2 mL of 1× Permeabilization Buffer (eBioscience) and stained with 0.4 µg of PE-conjugated anti-Foxp3 (clone FJK-16s, catalog number: 12-5773-80; eBioscience) at 4°C for 30 minutes. The cells were washed twice with 2 mL of 1× Permeabilization Buffer.
For each sample, we acquired 3000 to 10 000 events. The data were subsequently analyzed using FlowJo software (version 9.3.1; Tree Star, Inc, Ashland, OR).
Functional MDSC Assay
We measured Ly6G + Ly6C lo PMN-MDSCs' suppressive function based on their ability to inhibit antigen-specific CD8 + T cell proliferation. 28 We seeded CFSE-labeled splenocytes from Tg-RT1 mice at 2 × 10 5 cells/well in 96-round well plates in the presence of 1.6 µM peptide P18-I10 (Takara Bio Inc, Shiga, Japan). PMN-MDSCs were isolated from splenocytes derived from CT26bearing CD1d −/− mice 28 days post-tumor inoculation using a mouse MDSC isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Briefly, isolated splenocytes were incubated with anti-Ly6G-biotin and anti-biotin microbeads. The cells were subsequently applied to a MACS column, which was placed in the magnetic field of a MACS separator. The magnetically labeled Ly6G + cells were retained within the column. After removing the column from the magnetic field, the magnetically retained Gr-1 high Ly6G + cells were eluted as the positively selected cell fraction. To check the purity of PMN-MDSCs, some of the eluted cells were stained with anti-Ly6G-FITC, anti-Ly6C-PE, anti-CD11b-PECy7, and anti-CD45-APCCy7. Among the CD45 + CD11b + cells, approximately 90% were represented as the Ly6G + Ly6C lo population. We added purified PMN-MDSCs to CFSE-labeled Tg-RT1 splenoctyes at indicated ratios. After 96 hours post in vitro culture, we stained the cells with APCconjugated anti-CD8α (clone 53-6.7, catalog number: 100711, Biolegend). To assess CD8 + T cell proliferation, the cells were analyzed by flow cytometry.
In Vitro CTL Assay
We prepared single-cell suspensions of splenocytes from CT26-inoculated mice. After red blood cell lysis, we performed in vitro culture of 4 × 10 6 with 1 × 10 6 CT26 cells treated with 50 µg/mL mitomycin C in complete T cell media. 29 As a source of IL-2, rat T cell culture supplement, without ConA (Discovery Labware, Bedford, MA), was added to a final concentration of 10% on day 1. Cytotoxicity was assessed 7 days post in vitro culture, in a standard 4-hour 51 Cr-release assay with CT26 and BALB/c.3T3 (H-2 d ) fibroblast transfectant. This contained selectable marker genes (Neo) as targets at various E:T ratios in triplicate wells. We calculated the percent lysis as previously described. 30 
Statistical Analysis
The data were analyzed using the following tests: Student's t test, nonparametric Mann-Whitney U test, and log-rank test. To this end, the GraphPad Prism 6 software (version 6.0d; GraphPad Software, La Jolla, CA) was used. We considered P < .05 a statistically significant difference.
Results
Oral Administration of JTT Inhibits Tumor Growth in CD1d −/− Mice That Lack NKT Cells
To test the hypothesis that JTT acts as an anticancer agent in a model in which immunosuppression was partially relieved due to lack of NKT cells, we investigated whether JTT could enhance antitumor immunity in CD1d −/− mice. To this end, WT BALB/c or BALB-CD1d −/− mice were fed a control or JTT diet for 2 weeks. Subsequently, mice were subcutaneously inoculated with 5 × 10 4 CT26 cells. The same diet was provided to these mice for up to 4 weeks after the tumor cell challenge. Similar to our previous report, 12 JTT did not have any impact on tumor growth in WT mice ( Figure 1C) . In contrast, we confirmed that the tumors grew significantly slower in CD1d −/− mice than in WT mice 24, 25 ( Figure 1A and B ). Furthermore, as expected, we observed a significantly greater delay in tumor growth in CD1d −/− mice fed the JTT diet than those fed the control diet ( Figure  1D and E). However, almost all JTT-treated mice failed to reject the tumors completely ( Figure 1E ). These observations suggest that JTT exerts antitumor effects in CD1d −/− mice but not in WT mice.
JTT Enhances CD8 T Cell Activities in TILs
CD8 + TILs play pivotal roles in antitumor immune responses. 31 To this end, we measured the frequency of a degranulation marker CD107a + CD8 + TILs in tumors derived from CD1d −/− mice fed control diet or JTT diet. Measurements were performed 28 days post-tumor challenge. As shown in Figure 2A and B, the proportion of CD107a + CD8 + TILs in JTT mice was significantly higher than those in control mice. These observations suggest that an increased number of CD107a + CD8 + TILs might enhance antitumor immunity in JTT-treated CD1d −/− mice.
Tumor-Reactive CTLs Are Only Detected in CD1d −/− Mice Fed JTT Diet With Well-Controlled Tumors
Next, we analyzed the tumor-reactive CTLs in CT26challenged CD1d −/− mice. After 28 days from tumor inoculation, we cultured with mitomycin C-treated CT26, spleen cells derived from CD1d −/− mice fed the control or JTT diet, as shown in Figure 3A . Culture was performed in vitro for 7 days. Subsequently, their cytolytic activity against CT26 was evaluated by 51 Cr release assay. Among the 11 tumorbearing CD1d −/− mice fed a control diet tested, only one, with a tumor area <100 mm 2 , had marginal lytic activity against CT26 ( Figure 3B ). In contrast, 4 out of 10 JTT-diet mice, with a tumor area <100 mm 2 , had significant tumorspecific lytic activity ( Figure 3C , and Figure 3D right) while the remaining 6 mice, with tumor size >100 mm 2 , did not ( Figure 3C , and Figure 3D left) . These findings suggest that JTT may induce tumor-reactive CTLs in CD1d −/− mice where tumor growth was relatively suppressed.
Augmentation of Antitumor Effects Through JTT Requires CD8 + T Cells
We also planned to elucidate whether CD8 + T cells mediate the enhanced antitumor response in CD1d −/− mice fed the JTT diet. To this end, CD8 + T cells were depleted in vivo. As shown in Figure 4 , the anti-CD8 treatment in vivo abrogated antitumor effect in CD1d −/− mice fed JTT. These findings suggest a dependency on CD8 + T cells for an enhanced antitumor immunity by JTT.
JTT Has No Impact on the Number of CD4 + Treg Cells in CT26-Bearing CD1d −/− Mice
CD4 + Treg cells are known to be key regulators of tumor immune surveillance. 14 The abrogation of such Treg cells by anti-CD25 antibodies enhanced antitumor immunity in both WT [22] [23] [24] and CD1d −/−25 mice subcutaneously inoculated with CT26 tumors. Therefore, in the present study, we measured the number of CD4 + Treg cells in TILs and spleens in CT26-bearing CD1d −/− mice fed a control or JTT diet. Measurements were performed 28 days post-tumor challenge. When comparing the control-diet group and the JTT-diet group, we observed no difference in the number of CD4 + Treg cells in TILs (Figure 5A and B) and in spleens ( Figure 5C and D) . These findings suggest that JTT has no impact on the number of Treg cells in CT26-bearing CD1d −/− mice.
JTT Reduces the Number of PMN-MDSCs in TILs
Because MDSCs also play crucial roles in the immunosuppression of tumor-bearing hosts, 15, 32 we measured the frequency of MDSC in TILs and spleens derived from CT26-bearing CD1d −/− mice fed a control or JTT diet. Measurements were performed 28 days post-tumor challenge. In a recent study by Bronte et al, 33 it was shown that mouse MDSC are mainly divided into 2 types: CD11b + Ly6G + Ly6C lo PMN-MDSC; and CD11b + Ly6G − Ly6C hi M-MDSC. As shown in Figure 6A and B, compared with mice fed a control diet, there was a significant decrease of the frequency of PMN-MDSC in TILs in mice fed a JTT diet. In contrast, no significant differences were observed in the proportion of M-MDSC between control and JTT groups in TILs. Furthermore, there was no difference in the proportion of both types of MDSC between control and JTT groups in spleens ( Figure 6C and D) . To determine whether the reduced proportion of PMN-MDSCs in TILs was due to both the lack of NKT cells and JTT, we measured their frequency in TILs from JTT-treated WT mice. As expected, JTT had no impact on the frequency of PMN-MDSCs in TILs from WT mice ( Supplementary Figure 2A and B) . Interestingly, the frequency of splenic PMN-MDSCs from JTT-treated WT mice was significantly lower than that from control-diet mice ( Supplementary Figure 2C and D) . These observations suggest that the reduction of PMN-MDSC in TILs may contribute to the augmentation of antitumor immunity in CD1d −/− mice fed a JTT diet.
PMN-MDSC Derived From CT26-Bearing CD1d −/− Mice Fed the JTT Diet Are More Immunosuppressive
With the goal of elucidating PMN-MDSC's immunosuppressive function post CT26 inoculation, we isolated PMN-MDSC from spleens of CT26-bearing CD1d −/− mice as described in the Materials and Methods section. They were subsequently mixed with Tg-RT1 splenocytes in the presence of their epitope peptide P18-I10 for 4 days in vitro. As shown in Figure 6E and F, regardless of the diet, the addition of splenic PMN-MDSC derived from CT26bearing mice determined a dose-dependent reduction of CD8 + T cell proliferation. Interestingly, when compared with control-diet mice, the proliferation of CD8 + T cells was strongly suppressed by PMN-MDSC in JTT-diet mice ( Figure 6F ).
Discussion
In the present study, we demonstrated that oral administration of JTT inhibited tumor growth in CD1d-restricted NKT cell-deficient CD1d −/− mice, but not in immune-competent BALB/c mice ( Figure 1C and D) . These findings highlight the critical role JTT plays in enhancing antitumor immunity in a tumor-bearing host when immunosuppression is partially relieved as a consequence of lacking NKT cells. In addition, CD8 + T cells mediated JTT's antitumor immunity augmentation (Figure 4 ). However, in most CD1d −/− mice fed JTT, the tumors were not completely eradicated ( Figure  1E) . Moreover, we observed CTL reactive to CT26 exclusively in JTT-treated CD1d −/− mice with well-controlled tumors ( Figure 3C , and Figure 3D right) . Such findings suggest that JTT was not sufficient to maximize antitumor immunity in CD1d −/− mice. On the other hand, a previous study reported that, in the OVA-expressing EG7 murine tumor model, JTT enhanced tumor vaccine efficacy. 11 Additionally, Ishikawa et al 34 recently found that, in a B16 mouse melanoma model, JTT administration increased the inhibitory actions of anti-PD1 antibody against lung metastasis. Therefore, for the purpose of complete tumor rejection, the combination inhibiting the immunosuppressive pathway and tumor vaccine with JTT represents a promising strategy.
In a subcutaneous CT26 tumor model, CD4 + CD25 + Foxp3 + Treg cells are predominant immunosuppressive cells. They play a role in suppressing the antitumor T cell effector function in both WT and CD1d −/− mice. [22] [23] [24] [25] Consequently, we planned to elucidate whether JTT has any impact on CD4 + Treg cells in CD1d −/− mice. We analyzed these cells in TILs and spleens derived from CT26-bearing CD1d −/− mice fed a control or JTT diet. Our results clearly indicated that there is no impact on the number of Treg cells by JTT, in both TILs and spleens from CT26-bearing CD1d −/− mice ( Figure 5) .
A recent study has recognized MDSC to be one of the major obstacles to natural antitumor immunity and to numerous immunotherapies. 35 In order to address this issue, we next measured the frequency of MDSC in TILs and spleens derived from CT26-bearing CD1d −/− mice fed control or JTT diet. Measurements were performed 28 days is mediated by CD8 + T cells. We performed 2 independent experiments and pooled the results (n = 11 for control-diet group, n = 12 for JTT-diet group, and n = 9 for JTT diet + anti-CD8 group). P < .03 by log-rank test between the control and the JTT-diet group. P < .0001 by log-rank test between the control-or the JTT-diet group and JTT diet + anti-CD8 group.
post-tumor challenge. We observed that, when compared with control mice, the proportion of CD11b + Ly6G + Ly6C lo PMN-MDSC, but not CD11b + Ly6G − Ly6C hi M-MDSC, was significantly lower in TILs derived from JTT mice ( Figure 6A and B) . Furthermore, we observed a significant increase of the degranulation marker CD107a + CD8 + TILs in JTT mice versus control mice (Figure 2) . These data suggest that JTT's antitumor effect may be linked to a decrease in tumor-infiltrating PMN-MDSCs and an increase in CD107a + CTLs because of a significant tumor growth delay in JTT mice.
In the course of cancer progression, the production of various factors can be observed in tumor and stroma cells. Such factors are required to expand MDSCs via the promotion of myelopoiesis and the inhibition of differentiation, providing the necessary signals to endow their suppressive function. 36 Among these factors, vascular endothelial growth factor (VEGF) is known to be a chemoattractant for MDSCs 35 and is produced by MDSCs themselves. 37 A previous study has shown that JTT suppresses angiogenesis generated by B16 melanoma cells via VEGF inhibition. 38 Based on this knowledge, the reduction of PMN-MDSCs in TILs derived from JTT-treated mice may be explained by JTT's inhibition of VEGF. However, these findings warrant further investigation.
In recent preclinical and clinical studies, targeting MDSC represented a promising strategy to inhibit tumor growth and to prolong survival. However, due to extensive redundancy in MDSC inducers, depleting one mediator may be compensated by the presence of other mediators. As a result, while eliminating a single inducer may reduce the levels and suppressive potency of some MDSC, it is unlikely to eliminate all MDSC. 35 In line with this notion, while JTTtreated CD1d −/− mice had a significant reduction of tumorinfiltrating PMN-MDSC, we observed that JTT did not influence the proportion of tumor-infiltrating M-MDSC ( Figure 6A and B) . It also increased PMN-MDSC's immunosuppressive function ( Figure 6E and F). These results suggest that JTT alone is incapable of fully eliminating MDSC and their immunosuppressive activity. This may explain why tumors are not eradicated in JTT-treated mice. Thus, we believe that additional targeting therapies against MDSC are needed in conjunction with JTT to eliminate MDSC and reduce their immunosuppressive function more effectively. A possible additional drug to be combined with JTT is represented by a chemotherapeutic drug, gemcitabine (GEM). GEM selectively decreased the number of MDSC in cancer-bearing hosts. 39 In addition, the results of a clinical trial on pancreatic cancer patients indicated GEM treatment caused a dramatic decrease of PMN-MDSC. 40 Furthermore, a study on advanced biliary tract cancer has shown that the tumor was successfully treated by combining GEM single-agent chemotherapy with JTT. 41 A marginal impact on overall survival of advanced pancreatic cancer patients was observed following treatment with JTT combined with GEP (GEM + 5-fluorouracil + cisplatin) therapy. 42 While MDSC's role was not described in these 2 studies, their observations suggest that using a combinatorial cancer immunotherapy (ie, JTT and GEM) may represent a strategy for a more effective MDSC targeting. Additional studies are required in order to clarify whether, in JTT-treated CD1d −/− mice, GEM perform pivotal roles in the enhanced antitumor immunity.
It should be noted that JTT was able to help restore physical strength postsurgery and reduce the adverse effects of anticancer drugs or radiation therapy. 3 Furthermore, studies have shown that JTT ameliorated cancer-induced anorexia and cachexia in CT26 tumor-bearing mouse model. Specifically, this was achieved by altering the production of IL-6, MCP-1, PYY, and GLP-1. 43 Additionally, JTT is considered a relatively safe, low-cost, and effective medicine that has been used for over 800 years in East Asia, including Japan. 1 It has been available under the Japanese National Health Insurance System since 1976. Treatment with JTT has been used even though there is no reliable statistical evidence from large-scale controlled studies to support it. Based on these findings, we believe that JTT, which is a relatively safe and cost-effective medicine, could be important for both augmenting antitumor immunity and providing supportive care for tumor-bearing hosts' management.
In conclusion, to the best of our knowledge, the present study is the first to demonstrate that JTT enhances CD8 + T cell-mediated antitumor immunity in CD1d −/− mice lacking NKT cells. While further studies are needed to fully understand the underlying mechanism of JTT's anticancer effect, the present study provides a novel insight into JTT's use as antitumor adjuvant.
